This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Zosano Pharma Management

Management criteria checks 2/4

Key information

Steven Lo

Chief executive officer

US$2.0m

Total compensation

CEO salary percentage	26.2%
CEO tenure	3.1yrs
CEO ownership	0.06%
Management average tenure	3.1yrs
Board average tenure	3.1yrs

Recent management updates

Recent updates

Can Zosano Pharma (NASDAQ:ZSAN) Afford To Invest In Growth?

Nov 02

Is Zosano Pharma (NASDAQ:ZSAN) Weighed On By Its Debt Load?

Jun 29

Data supports long-term benefit of Zosano's migraine candidate; shares surge 23%

May 26

Zosano Pharma: Early PK+Safety Study In Q3 2021 May Breathe New Life Into This Biotech

Apr 30

Zosano shares rise on migraine treatment NDA resubmission update

Apr 26

Auditors Have Doubts About Zosano Pharma (NASDAQ:ZSAN)

Mar 15

Zosano Pharma up 21% following FDA feedback on Qtrypta application; presents Qtrypta data in migraine

Feb 01

Zosano Pharma requests FDA meeting for its Qtrypta application

Jan 04

Zosano Pharma EPS misses by $0.01

Nov 13

CEO Compensation Analysis

How has Steven Lo's remuneration changed compared to Zosano Pharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2022	n/a	n/a	-US$55m
Dec 31 2021	US$2m	US$533k	-US$30m
Sep 30 2021	n/a	n/a	-US$31m
Jun 30 2021	n/a	n/a	-US$31m
Mar 31 2021	n/a	n/a	-US$33m
Dec 31 2020	US$1m	US$526k	-US$33m
Sep 30 2020	n/a	n/a	-US$34m
Jun 30 2020	n/a	n/a	-US$35m
Mar 31 2020	n/a	n/a	-US$37m
Dec 31 2019	US$875k	US$106k	-US$38m

Compensation vs Market: Steven's total compensation ($USD2.03M) is above average for companies of similar size in the US market ($USD748.73K).

Compensation vs Earnings: Steven's compensation has increased whilst the company is unprofitable.

CEO

Steven Lo (55 yo)

3.1yrs

Tenure

US$2,032,101

Compensation

Mr. Steven Lo has been Director at Zosano Pharma Corporation since October 2019 and serves as its President and Chief Executive Officer since October 21, 2019 and has been its Senior Vice President of Oper...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Steven Lo	Senior VP of Operations	3.1yrs	US$2.03m	0.055% $ 1.9
Christine Matthews	Chief Financial Officer	2.8yrs	US$675.66k	0.012% $ 0.4
Lu Liu	Vice President of Technical Operations	3.8yrs	no data	no data
Jeffrey Quillen	Secretary	no data	no data	no data

3.1yrs

Average Tenure

Experienced Management: ZSAN.Q's management team is considered experienced (3.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Steven Lo	Senior VP of Operations	3.1yrs	US$2.03m	0.055% $ 1.9
Kenneth Greathouse	Lead Independent Director	5.1yrs	US$97.84k	0.017% $ 0.6
Linda Grais	Independent Director	3.8yrs	US$96.98k	0.0044% $ 0.1
Kathy McGee	Independent Director	1.5yrs	US$89.00k	0% $ 0
Elaine Yang	Independent Director	less than a year	US$46.92k	no data

3.1yrs

Average Tenure

63yo

Average Age

Experienced Board: ZSAN.Q's board of directors are considered experienced (3.1 years average tenure).

This company is no longer active

Zosano Pharma Management

Management criteria checks 2/4

Key information

Recent management updates

Joseph “Jay” P. Hagan Resigns as Director of the Board of Directors of Zosano Pharma Corporation

Steven A. Elms Tenders His Resignation as Director of the Board of Directors of Zosano Pharma Corporation

Zosano Pharma Corporation Announces John Walker, Chairman of the Board of Directors to Retire from the Board

Recent updates

Emergex USA Corporation completed the acquisition of Substantially all assets of Zosano Pharma Corporation for $1 million.

Emergex USA Corp. agreed to acquire Substantially all assets of Zosano Pharma Corporation (OTCPK:ZSAN.Q) for $1.3 million.

Motion for Case Conversion Filed for Zosano Pharma Corporation

Motion for Asset Sale Filed by Zosano Pharma Corporation

Zosano Pharma Corporation to Delist from Nasdaq

Zosano Pharma Corporation Filed for Bankruptcy

Joseph “Jay” P. Hagan Resigns as Director of the Board of Directors of Zosano Pharma Corporation

Zosano Pharma Corporation Reports Impairment Charges for the First Quarter Ended March 31, 2022

Consensus forecasts updated

Steven A. Elms Tenders His Resignation as Director of the Board of Directors of Zosano Pharma Corporation

Price target decreased to US$21.00

Consensus revenue estimates increase by 95%

Zosano Pharma Corporation Receives a Response Letter from the U.S. Food and Drug Administration with Regard to the Company’s January 18, 2022 Resubmission of the 505(b)(2) New Drug Application for M207

Zosano Pharma Corporation has completed a Composite Units Offering in the amount of $15.375 million.

Zosano Pharma Corporation has completed a Composite Units Offering.

Zosano Pharma Corporation Resubmits its M207 (Zolmitriptan Transdermal Microneedle System) 505(B)(2) New Drug Application to the U.S. Food and Drug Administration

Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of A Trivalent Influenza Vaccine Formulated on Its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine At A Higher Dose

Can Zosano Pharma (NASDAQ:ZSAN) Afford To Invest In Growth?

Is Zosano Pharma (NASDAQ:ZSAN) Weighed On By Its Debt Load?

Consensus forecasts updated

Consensus revenue estimates increase to US$2.08m

Zosano Pharma Corporation Announces Publication of Clinical Data Regarding the Long-Term Use of Qtrypta for the Treatment of Acute Migraine in the Journal of Headache and Pain

Data supports long-term benefit of Zosano's migraine candidate; shares surge 23%

Consensus forecasts updated

Zosano Pharma: Early PK+Safety Study In Q3 2021 May Breathe New Life Into This Biotech

Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDA

Zosano shares rise on migraine treatment NDA resubmission update

Consensus revenue estimates increase to US$5.17m

Auditors Have Doubts About Zosano Pharma (NASDAQ:ZSAN)

Earnings miss expectations

Zosano Pharma Corporation Announces John Walker, Chairman of the Board of Directors to Retire from the Board

Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA

New 90-day high: US$1.93

Zosano Pharma Corporation Announces NDA Resubmission Plans Following Type A Meeting with FDA

Zosano Pharma up 21% following FDA feedback on Qtrypta application; presents Qtrypta data in migraine

New 90-day high: US$0.81

Zosano Pharma Requests Type A Meeting with the Fda to Review Resubmission Plans for Qtrypta™ New Drug Application

Zosano Pharma requests FDA meeting for its Qtrypta application

Bragar Eagel & Squire, P.C. Reminds Investors of Class Action Lawsuit Filed Against Zosano Pharma Corporation

Pomerantz LLP Reminds Shareholders with Losses on Their Investment in Zosano Pharma Corporation of Class Action Lawsuit and Upcoming Deadline

Zosano Pharma EPS misses by $0.01

New 90-day low: US$0.36

Rosen Announces Filing of Securities Class Action Lawsuit Against Zosano Pharma Corporation

Price target lowered to US$2.00

New 90-day low: US$0.64

New 90-day low: US$0.70

Zosano Pharma Corporation Receives Discipline Review Letter from the U.S. Food and Drug Administration in Connection with the Qtrypta

Zosano Pharma Corporation has completed a Follow-on Equity Offering in the amount of $20.782018 million.

New 90-day high - US$1.69

New 90-day high - US$1.22

Zosano Pharma Corporation(NasdaqCM:ZSAN) dropped from Russell Microcap Growth Index

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age